The Obesity Drug Race Moves Past Ozempic with a Shot Targeting Three Hormones

Eli Lilly’s retatrutide produced up to 30.3% average weight loss in phase 3 trials. Approval is not expected before 2027 at the earliest.

Have A Referral?